Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BAY 2395840 in Participants With Moderate Renal Impairment and in Healthy Male and Female Participants With Normal Renal Function

Next Previous
Trial Profile

An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BAY 2395840 in Participants With Moderate Renal Impairment and in Healthy Male and Female Participants With Normal Renal Function

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BAY 2395840 (Primary)
  • Indications Diabetic nephropathies; Inflammation; Neuropathic pain
  • Focus Pharmacokinetics
  • Sponsors Bayer

Most Recent Events

  • 17 Apr 2023 Status changed from not yet recruiting to withdrawn prior to enrolment. ( Discontinuation of program.)
  • 02 Feb 2023 Planned initiation date changed from 6 Mar 2023 to 15 May 2023.
  • 07 Nov 2022 Planned End Date changed from 7 Jul 2023 to 12 Oct 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top